Business Context and Reporting Period
Company: Transdel Pharmaceuticals, Inc. (Note: Metadata listed "Harrow, Inc." but filing content identifies Transdel Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: A development-stage specialty pharmaceutical company focused on non-invasive, topically delivered products. The lead product candidate is Ketotransdel® (ketoprofen) for acute pain management. The company also pursues cosmetic/cosmeceutical products utilizing its Transdel® delivery technology.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,358,613) | $(2,849,264) |
| Operating Loss | $(1,367,509) | $(2,858,318) |
| Cash and Cash Equivalents (End of Period) | $1,042,614 | $2,902,221 |
| Total Assets | $1,242,037 | $1,672,084 |
| Total Liabilities | $1,469,251 | $1,094,873 |
| Stockholders' Deficit | $(227,214) | $577,211 |
| Net Cash Used in Operating Activities | $(1,547,159) | $(2,208,810) |
| Net Cash Provided by Financing Activities | $1,000,000 | $0 |
Debt: As of June 30, 2010, the company held a Senior Convertible Promissory Note of $1,000,000 (plus accrued interest) issued in April 2010. Total liabilities increased primarily due to this new debt and accrued separation expenses.
Material Changes vs. Prior Period
- Revenue: No revenue recognized in either period; the company remains in the development stage.
- Net Loss: Net loss decreased by approximately $1.49 million (52%) compared to the prior six-month period, primarily due to a significant reduction in Research and Development (R&D) expenses.
- R&D Expenses: Decreased from $2.03 million to $0.20 million. This reduction reflects the completion of the first Phase 3 clinical trial for Ketotransdel® in the prior year, with only minimal administrative costs incurred in the current period.
- Selling, General and Administrative (SG&A) Expenses: Increased from $0.83 million to $1.17 million. This increase was driven by one-time separation costs of approximately $416,000 related to the resignation of the former CEO (salary accrual and stock option modifications).
- Liquidity: Cash balances decreased by approximately $547,000 during the period. However, the company raised $1.0 million via a senior convertible note in April 2010, which offset operating cash burn.
- Liabilities: Total liabilities increased by approximately $374,000, largely due to the new $1.0 million convertible note and accrued separation expenses, partially offset by reductions in accounts payable and accrued Phase 3 expenses.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has incurred cumulative losses of $16.3 million since inception and has no revenue. Continuation depends on obtaining additional financing.
- Outlook: Management anticipates having adequate resources to fund operations through the fourth quarter of 2010. However, additional funding is required to execute a second Phase 3 clinical trial, which is necessary for FDA approval of Ketotransdel®.
- Unusual Items:
- CEO Separation: A one-time expense of ~$416,000 was recorded for the former CEO's separation agreement (salary continuation and accelerated stock option vesting).
- Gain on Forgiveness: A gain of $26,299 was recognized from the forgiveness of a vendor liability upon the issuance of the new convertible note.
- Risks:
- Failure to secure additional financing before the end of 2010 could force the company to cease operations.
- Regulatory uncertainty regarding the FDA's acceptance of the first Phase 3 trial data and the requirement for a second trial.
- Dependence on third-party manufacturers and contract research organizations.
- Stock price volatility and classification as a "penny stock."
Investor Verification Checklist
- Runway: Verify if the company has secured the additional financing required to fund the second Phase 3 clinical trial, as current cash ($1.04M) is projected to last only through Q4 2010.
- Regulatory Status: Confirm the FDA's official stance on the first Phase 3 trial results and the specific design requirements for the mandatory second Phase 3 trial.
- Debt Covenants: Review the terms of the $1.0 million Senior Convertible Note issued in April 2010, specifically regarding conversion rates, interest rates (7.5%), and maturity (April 2012).
- Commercial Partnerships: Assess the progress of licensing agreements with JH Direct, LLC and Jan Marini Skin Research, Inc., as these represent potential near-term royalty revenue streams.
- Stock Dilution: Monitor future equity issuances, as the company may need to raise capital through dilutive equity offerings or convertible debt to survive.